Company News from Forest Labs and Abbott Labs

Share this article:
Forest Labs agreed to settle government civil allegations that it improperly marketed antidepressants Celexa and Lexapro, as well as its Levothroid thyroid drug, the firm revealed in an SEC filing. The amount is covered under a $170,000 cash reserve. But Forest termed the pact an “agreement in principle” that is still not final and noted an ongoing criminal probe.
 
Separately, Abbott Labs said in an SEC filing that the US Department of Justice is investigating promotional activities for its CNS drug Depakote. The government is seeking to determine whether sales and marketing practices may have violated the Federal False Claims Act, the Food and Drug Cosmetic Act or the Anti-Kickback Statute.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.